Clinical Trials for CC-223

1 Open Trial

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCTHN1242
10/24/2012
A Phase IB, Multi-Center,Open-Label Study of the MTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.